1 withdrawn. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Withdrawn 1 |
Follow Congenital Bleeding Disorder: new trials by email Literature Review of Congenital Bleeding Disorder trials Research Report on Congenital Bleeding Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven® in Healthy Male Subjects activated recombinant human factor VII, eptacog alfa (activated) - Congenital Bleeding Disorder, Haemophilia A | Phase 1 | Withdrawn | Novo Nordisk A/S | 2014-03-01 | 2014-03-26 |
Hemophilia A (1) · Hemophilia B (1)
Blood Coagulation Disorders (1) · Blood Coagulation Disorders, Inherited (1) · Coagulation Protein Disorders (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Genetic Diseases, Inborn (1) · Genetic Diseases, X-Linked (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Hemorrhagic Disorders (1)
Factor VII (1)
Novo Nordisk A/S (1)